Temodar is an orally available cytotoxic drug indicated for the treatment of GBM. It is an alkylating
agent that triggers cell death by alkylating guanine residues, inhibiting DNA replication and
subsequent cancer cell proliferation (Friedman et al., 2000).
Temodar (temozolomide; Merck & Co) achieved blockbuster sales after becoming the standard-of-care
treatment for newly diagnosed glioblastoma multiforme (GBM) following its approval in 1999.
However, the entrance of generic versions of temozolomide has eroded the drug’s sales since 2011 in
the EU and 2013 in the US. Generic versions of temozolomide will continue to negatively impact
Temodar’s sales as they are increasingly used in the standard-of-care Stupp protocol (radiotherapy
plus concomitant and adjuvant temozolomide) for newly diagnosed disease.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.